Go Pro
→ The New Kings of Cantillon (From Porter & Company) (Ad)tc pixel Free IDHC Stock Alerts

Integrated Diagnostics (IDHC) Competitors

Integrated Diagnostics logo
GBX 0.51 -0.03 (-5.86%)
As of 12:42 PM Eastern
Compare

IDHC vs. AGL, GENI, PRM, VRCI, and MXCT

Should you buy Integrated Diagnostics stock or one of its competitors? Integrated Diagnostics's main competitors and comparable companies include ANGLE (AGL), GENinCode (GENI), Proteome Sciences (PRM), Verici Dx (VRCI), and MaxCyte (MXCT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does Integrated Diagnostics compare to ANGLE?

Integrated Diagnostics (LON:IDHC) and ANGLE (LON:AGL) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, risk, analyst recommendations, earnings and media sentiment.

7.7% of Integrated Diagnostics shares are owned by institutional investors. Comparatively, 17.5% of ANGLE shares are owned by institutional investors. 71.3% of Integrated Diagnostics shares are owned by insiders. Comparatively, 2.7% of ANGLE shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, ANGLE had 1 more articles in the media than Integrated Diagnostics. MarketBeat recorded 1 mentions for ANGLE and 0 mentions for Integrated Diagnostics. Integrated Diagnostics' average media sentiment score of 0.00 equaled ANGLE'saverage media sentiment score.

Company Overall Sentiment
Integrated Diagnostics Neutral
ANGLE Neutral

Integrated Diagnostics has a net margin of 17.20% compared to ANGLE's net margin of -1,444.04%. Integrated Diagnostics' return on equity of 38.79% beat ANGLE's return on equity.

Company Net Margins Return on Equity Return on Assets
Integrated Diagnostics17.20% 38.79% 9.69%
ANGLE -1,444.04%-191.36%-29.89%

Integrated Diagnostics has a beta of 0.436, indicating that its share price is 56% less volatile than the broader market. Comparatively, ANGLE has a beta of 0.22, indicating that its share price is 78% less volatile than the broader market.

Integrated Diagnostics has higher revenue and earnings than ANGLE. ANGLE is trading at a lower price-to-earnings ratio than Integrated Diagnostics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Integrated Diagnostics£8.35B0.00£4.01T£250.030.00
ANGLE£2.62M2.89-£21.76M-£4.80N/A

Summary

Integrated Diagnostics beats ANGLE on 9 of the 12 factors compared between the two stocks.

How does Integrated Diagnostics compare to GENinCode?

GENinCode (LON:GENI) and Integrated Diagnostics (LON:IDHC) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, media sentiment, analyst recommendations, institutional ownership and profitability.

In the previous week, GENinCode's average media sentiment score of 0.00 equaled Integrated Diagnostics'average media sentiment score.

Company Overall Sentiment
GENinCode Neutral
Integrated Diagnostics Neutral

Integrated Diagnostics has a net margin of 17.20% compared to GENinCode's net margin of -185.47%. Integrated Diagnostics' return on equity of 38.79% beat GENinCode's return on equity.

Company Net Margins Return on Equity Return on Assets
GENinCode-185.47% -409.40% -63.99%
Integrated Diagnostics 17.20%38.79%9.69%

11.4% of GENinCode shares are held by institutional investors. Comparatively, 7.7% of Integrated Diagnostics shares are held by institutional investors. 8.4% of GENinCode shares are held by company insiders. Comparatively, 71.3% of Integrated Diagnostics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

GENinCode has a beta of 0.557, meaning that its share price is 44% less volatile than the broader market. Comparatively, Integrated Diagnostics has a beta of 0.436, meaning that its share price is 56% less volatile than the broader market.

Integrated Diagnostics has higher revenue and earnings than GENinCode. GENinCode is trading at a lower price-to-earnings ratio than Integrated Diagnostics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
GENinCode£3.08M2.09-£6.10M-£2.08N/A
Integrated Diagnostics£8.35B0.00£4.01T£250.030.00

Summary

Integrated Diagnostics beats GENinCode on 8 of the 11 factors compared between the two stocks.

How does Integrated Diagnostics compare to Proteome Sciences?

Integrated Diagnostics (LON:IDHC) and Proteome Sciences (LON:PRM) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, valuation, profitability, institutional ownership, earnings and analyst recommendations.

7.7% of Integrated Diagnostics shares are held by institutional investors. Comparatively, 0.0% of Proteome Sciences shares are held by institutional investors. 71.3% of Integrated Diagnostics shares are held by insiders. Comparatively, 36.7% of Proteome Sciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Integrated Diagnostics has a beta of 0.436, indicating that its share price is 56% less volatile than the broader market. Comparatively, Proteome Sciences has a beta of 0.148, indicating that its share price is 85% less volatile than the broader market.

Integrated Diagnostics has higher revenue and earnings than Proteome Sciences. Proteome Sciences is trading at a lower price-to-earnings ratio than Integrated Diagnostics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Integrated Diagnostics£8.35B0.00£4.01T£250.030.00
Proteome Sciences£3.76M1.73-£4.08M-£1.04N/A

In the previous week, Proteome Sciences had 1 more articles in the media than Integrated Diagnostics. MarketBeat recorded 1 mentions for Proteome Sciences and 0 mentions for Integrated Diagnostics. Integrated Diagnostics' average media sentiment score of 0.00 equaled Proteome Sciences'average media sentiment score.

Company Overall Sentiment
Integrated Diagnostics Neutral
Proteome Sciences Neutral

Integrated Diagnostics has a net margin of 17.20% compared to Proteome Sciences' net margin of -81.50%. Integrated Diagnostics' return on equity of 38.79% beat Proteome Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Integrated Diagnostics17.20% 38.79% 9.69%
Proteome Sciences -81.50%33.80%-19.25%

Summary

Integrated Diagnostics beats Proteome Sciences on 10 of the 12 factors compared between the two stocks.

How does Integrated Diagnostics compare to Verici Dx?

Verici Dx (LON:VRCI) and Integrated Diagnostics (LON:IDHC) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, institutional ownership, risk, profitability and earnings.

In the previous week, Verici Dx's average media sentiment score of 0.00 equaled Integrated Diagnostics'average media sentiment score.

Company Overall Sentiment
Verici Dx Neutral
Integrated Diagnostics Neutral

Integrated Diagnostics has a net margin of 17.20% compared to Verici Dx's net margin of -193.05%. Integrated Diagnostics' return on equity of 38.79% beat Verici Dx's return on equity.

Company Net Margins Return on Equity Return on Assets
Verici Dx-193.05% -138.93% -26.14%
Integrated Diagnostics 17.20%38.79%9.69%

Verici Dx has a beta of 1.256, meaning that its stock price is 26% more volatile than the broader market. Comparatively, Integrated Diagnostics has a beta of 0.436, meaning that its stock price is 56% less volatile than the broader market.

15.7% of Verici Dx shares are held by institutional investors. Comparatively, 7.7% of Integrated Diagnostics shares are held by institutional investors. 1.2% of Verici Dx shares are held by company insiders. Comparatively, 71.3% of Integrated Diagnostics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Integrated Diagnostics has higher revenue and earnings than Verici Dx. Verici Dx is trading at a lower price-to-earnings ratio than Integrated Diagnostics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Verici Dx£3.66M1.37-£6.56M-£0.90N/A
Integrated Diagnostics£8.35B0.00£4.01T£250.030.00

Summary

Integrated Diagnostics beats Verici Dx on 8 of the 11 factors compared between the two stocks.

How does Integrated Diagnostics compare to MaxCyte?

Integrated Diagnostics (LON:IDHC) and MaxCyte (LON:MXCT) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, dividends, analyst recommendations, earnings, institutional ownership, profitability, valuation and risk.

Integrated Diagnostics has a beta of 0.436, suggesting that its stock price is 56% less volatile than the broader market. Comparatively, MaxCyte has a beta of 1.13, suggesting that its stock price is 13% more volatile than the broader market.

Integrated Diagnostics has higher revenue and earnings than MaxCyte. MaxCyte is trading at a lower price-to-earnings ratio than Integrated Diagnostics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Integrated Diagnostics£8.35B0.00£4.01T£250.030.00
MaxCyte£32.29M0.05-£45.08M-£40.00N/A

7.7% of Integrated Diagnostics shares are held by institutional investors. Comparatively, 24.0% of MaxCyte shares are held by institutional investors. 71.3% of Integrated Diagnostics shares are held by company insiders. Comparatively, 1.9% of MaxCyte shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Integrated Diagnostics' average media sentiment score of 0.00 equaled MaxCyte'saverage media sentiment score.

Company Overall Sentiment
Integrated Diagnostics Neutral
MaxCyte Neutral

Integrated Diagnostics has a net margin of 17.20% compared to MaxCyte's net margin of -119.69%. Integrated Diagnostics' return on equity of 38.79% beat MaxCyte's return on equity.

Company Net Margins Return on Equity Return on Assets
Integrated Diagnostics17.20% 38.79% 9.69%
MaxCyte -119.69%-11.59%-11.07%

Summary

Integrated Diagnostics beats MaxCyte on 8 of the 11 factors compared between the two stocks.

Get Integrated Diagnostics News Delivered to You Automatically

Sign up to receive the latest news and ratings for IDHC and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IDHC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

IDHC vs. The Competition

Export
MetricIntegrated DiagnosticsLife Sciences Tools & Services IndustryHealthcare SectorLON Exchange
Market Cap£2.99M£10.21B£7.40B£2.92B
Dividend Yield1.56%1.46%2.53%6.17%
P/E Ratio0.0063.20272.19367.32
Price / Sales0.00111.26631.7683,741.35
Price / CashN/A27.0979.8927.89
Price / Book0.0037.5113.147.02
Net Income£4.01T£56.67B£3.47B£5.89B
7 Day Performance-1.53%2.12%1.38%0.89%
1 Month Performance-3.02%10.71%8.62%3.27%
1 Year Performance2.80%25.70%25.90%22.28%

Integrated Diagnostics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
IDHC
Integrated Diagnostics
N/AGBX 0.51
-5.9%		N/A+27.0%£2.99M£8.35B0.006,692
AGL
ANGLE
N/AGBX 2.35
-11.3%		N/A-63.8%£7.58M£2.62MN/A650
GENI
GENinCode
N/AGBX 0.94
+6.2%		N/A-36.8%£7.08M£3.08MN/A2,300
PRM
Proteome Sciences
N/AGBX 2
+11.4%		N/A-56.9%£7.01M£3.76MN/A240
VRCI
Verici Dx
N/AGBX 0.21
-16.0%		N/A-58.8%£4.80M£3.66MN/A19

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:IDHC) was last updated on 8/26/2026 by MarketBeat.com Staff.
From Our Partners
Someone just dumped the biggest gold fund.
Investors pulled 2.9 billion dollars from the world's largest gold fund in a single day this March, pushing to...
Behind the Markets | Sponsoredtc pixel
A $382 trillion migration and the position no one is talking about
Trump just signed a law requiring America's entire $382 trillion financial system to migrate to a new money ne...
Awesomely | Sponsoredtc pixel
Bezos… DOOMED
A single FCC filing hints Elon Musk is planning his biggest project yet - bigger than Tesla, SpaceX, and X com...
Paradigm Press | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
Your withdrawal order could cost you in taxes
If you have $2M or more saved, the 4% rule points to roughly $92,000 a year - but it's a single-variable answe...
SmartAsset | Sponsoredtc pixel
The trade I’ve been waiting for since 2011
Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...
Traders Agency | Sponsoredtc pixel
Jeff Brown and Marc Chaikin's latest AI prediction explained
Jeff Brown and Marc Chaikin - the duo who identified Nvidia a decade ago - are forecasting that Elon Musk's AI...
Brownstone Research | Sponsoredtc pixel
Buy this stock today
Most tech companies skip dividends entirely. This one doesn't, paying shareholders like clockwork while flying...
Chaikin Analytics | Sponsoredtc pixel